Press Releases

DAY HI:
DAY LOW:
VOLUME:

Data Provided by Refinitiv. Minimum 15 minutes delayed.

Press Releases

Date Title Format
Dec 06, 2022
BOSTON --(BUSINESS WIRE)--Dec. 6, 2022-- Spectrum Pharmaceuticals, Inc. (NasdaqGS: SPPI), a biopharmaceutical company focused on novel and targeted oncology announced today that ROLVEDON (eflapegrastim-xnst) has been added to the latest National Comprehensive Cancer Network® Supportive Care
Dec 05, 2022
-- Commercial employees (non-executive) who were hired specifically for the launch of ROLVEDON™ (eflapegrastim-xnst) injection are the recipients of this grant -- BOSTON --(BUSINESS WIRE)--Dec. 5, 2022-- Spectrum Pharmaceuticals (NasdaqGS: SPPI), a biopharmaceutical company focused on novel and
Nov 25, 2022
— Immediately de-prioritizes poziotinib program, accelerates cost reductions, including 75% reduction in R&D related workforce — — Spectrum to explore strategic alternatives for the poziotinib program, including partnerships and business development opportunities — BOSTON --(BUSINESS WIRE)--Nov.
Nov 10, 2022
-- ROLVEDON™ (eflapegrastim-xnst) injection is now commercially available -- -- Cash runway expected to extend through 2024 -- -- Management to host webcast and conference call today at 4:30 p.m. ET / 1:30 p.m. PT -- BOSTON --(BUSINESS WIRE)--Nov. 10, 2022-- Spectrum Pharmaceuticals, Inc.
Nov 03, 2022
BOSTON --(BUSINESS WIRE)--Nov. 3, 2022-- Spectrum Pharmaceuticals, Inc. (NasdaqGS: SPPI), a biopharmaceutical company focused on novel and targeted oncology therapies, today announced it will host a conference call to discuss the third quarter 2022 financial results and provide a corporate update
Oct 21, 2022
-- Distribution partners stocked with product and ready to sell into estimated $2 billion market -- BOSTON --(BUSINESS WIRE)--Oct. 21, 2022-- Spectrum Pharmaceuticals, Inc. (NasdaqGS: SPPI) (“Spectrum” or the “Company”), a biopharmaceutical company focused on novel and targeted oncology therapies,
Sep 23, 2022
-- Multiple tranche debt financing provides Spectrum with up to $65 million -- -- Funding provides additional capital to optimize commercial launch of ROLVEDON™ -- -- Cash runway extended through 2024 -- BOSTON --(BUSINESS WIRE)--Sep. 23, 2022-- Spectrum Pharmaceuticals, Inc.
Sep 22, 2022
BOSTON --(BUSINESS WIRE)--Sep. 22, 2022-- Spectrum Pharmaceuticals (NasdaqGS: SPPI) (“Spectrum” or the “Company”), a biopharmaceutical company focused on novel and targeted oncology therapies, today announced that the U.S. Food and Drug Administration’s (“FDA”) Oncologic Drugs Advisory Committee
Sep 10, 2022
BOSTON --(BUSINESS WIRE)--Sep. 10, 2022-- Spectrum Pharmaceuticals, Inc. (NasdaqGS: SPPI), a biopharmaceutical company focused on novel and targeted oncology therapies, today announced data from a poster presentation titled: High Activity of Poziotinib in G778_P780dup HER2 Exon 20 Insertion
Sep 09, 2022
First novel Long-Acting GCSF (LA-GCSF) product approved in over 20 years ROLVEDON ™ developed using proprietary LAPSCOVERY ™ technology with a differentiated molecular structure and proven safety and efficacy profile Commercial team ready to launch with product available in the fourth quarter
Sep 05, 2022
BOSTON --(BUSINESS WIRE)--Sep. 5, 2022-- Spectrum Pharmaceuticals (NasdaqGS: SPPI), a biopharmaceutical company focused on novel and targeted oncology therapies, today announced a poster presentation titled: High Activity of Poziotinib in G778_P780dup HER2 Exon 20 Insertion Mutations in Non-Small
Aug 11, 2022
Eflapegrastim BLA under FDA review; PDUFA date September 9, 2022 FDA completes re-inspection of drug substance manufacturing facility for eflapegrastim Poziotinib NDA under FDA review with ODAC meeting on September 22, 2022 Management to host webcast and conference call today at 8:30 a.m.
Jul 29, 2022
HENDERSON, Nev. --(BUSINESS WIRE)--Jul. 29, 2022-- Spectrum Pharmaceuticals (NasdaqGS: SPPI), a biopharmaceutical company focused on novel and targeted oncology therapies, today announced it will host a conference call to discuss the second quarter 2022 financial results and provide a corporate
Jun 02, 2022
HENDERSON, Nev. --(BUSINESS WIRE)--Jun. 2, 2022-- Spectrum Pharmaceuticals (NasdaqGS: SPPI), a biopharmaceutical company focused on novel and targeted oncology therapies, today announced that management will participate in two upcoming investor conferences: A fireside chat presentation at the
May 26, 2022
Reduced circulating tumor DNA (ctDNA) and circulating free DNA (cfDNA) levels were associated with tumor shrinkage in patients that responded to poziotinib treatment Poziotinib has received Fast Track designation from FDA and a Prescription Drug User Fee Act (PDUFA) date of November 24, 2022
May 17, 2022
HENDERSON, Nev. --(BUSINESS WIRE)--May 17, 2022-- Spectrum Pharmaceuticals (NasdaqGS: SPPI), a biopharmaceutical company focused on novel and targeted oncology therapies, today announced that management will participate in the upcoming H.C. Wainwright Global Investment Conference , to be held
May 12, 2022
Resubmitted eflapegrastim BLA accepted for review by the FDA, PDUFA date September 9, 2022 Poziotinib NDA under review by FDA with PDUFA date of November 24, 2022 and will be discussed at ODAC meeting in September Positive poziotinib results in treatment naïve patients with NSCLC harboring HER2
May 11, 2022
HENDERSON, Nev. --(BUSINESS WIRE)--May 11, 2022-- Spectrum Pharmaceuticals (NasdaqGS: SPPI), a biopharmaceutical company focused on novel and targeted oncology therapies, today announced the appointment of Nora Brennan as Chief Financial Officer effective May 25, 2022 . Ms.
May 06, 2022
HENDERSON, Nev. --(BUSINESS WIRE)--May 6, 2022-- Spectrum Pharmaceuticals (NasdaqGS: SPPI), a biopharmaceutical company focused on novel and targeted oncology therapies, today announced it will host a conference call to discuss the first quarter 2022 financial results and provide a corporate update
May 05, 2022
HENDERSON, Nev. --(BUSINESS WIRE)--May 5, 2022-- Spectrum Pharmaceuticals (NasdaqGS: SPPI), a biopharmaceutical company focused on novel and targeted oncology therapies, today announced the appointment of Brittany Bradrick to its Board of Directors. Brittany is an accomplished leader with 25 years
Displaying 1 - 20 of 887